title: Inhibitory effect of a traditional Chinese medicine, Juzen-taiho-to, on progressive growth of weakly malignant clone cells derived from murine fibrosarcoma.
abstract: We have investigated the inhibitory effect of oral administration of Juzen-taiho-to, a Kampo (Chinese herbal) medicine, on progressive growth of a mouse fibrosarcoma. Spontaneously regressive QR-32 tumor cells were able to grow progressively in vivo when coimplanted s.c. with a foreign body, gelatin sponge, whereas QR-32 cells alone gradually grew for over 15 days after inoculation and thereafter regressed for up to 25 days. Oral administration of Juzen-taiho-to (40 mg/day/mouse) for 7 days after inoculation of QR-32 cells with gelatin sponge resulted in significant inhibition of tumor growth and prolongation of the survival of the tumor-bearing mice. This growth-inhibitory effect of Juzen-taiho-to observed on day 25 was dose-dependent over the dose range from 4 to 40 mg/day. Treatment with Juzen-taiho-to for 7 days before tumor inoculation with gelatin sponge also significantly suppressed tumor growth examined on day 25, as did the administration of bismuth subnitrate, which is well known to induce metallothionein, an antioxidant. On the other hand, inoculation of progressed tumor cells (QRsP) resulted in growth without gelatin sponge, leading to death in syngeneic mice. Administration of Juzen-taiho-to for 7 days after inoculation of QRsP cells resulted in a decrease of the tumor growth and prolongation of the survival of mice, but the effect was less than that on the growth of QR-32 regressor tumor after coimplantation with gelatin sponge. These results suggest that the inhibitory effect of Juzen-taiho-to is partly associated with prevention of gelatin sponge-elicited progressive growth, probably mediated by endogenous factors including antioxidant substances, in addition to the augmentation of host-mediated antitumor activity.
authors.affiliation: Department of Pathogenic Biochemistry, Research Institute for Wakan-Yaku, Toyama, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ohnishi
authors.forename: H
authors.initials: H
authors.lastname: Fujii
authors.forename: F
authors.initials: F
authors.lastname: Kimura
authors.forename: T
authors.initials: T
authors.lastname: Mishima
authors.forename: J
authors.initials: J
authors.lastname: Murata
authors.forename: K
authors.initials: K
authors.lastname: Tazawa
authors.forename: M
authors.initials: M
authors.lastname: Fujimaki
authors.forename: F
authors.initials: F
authors.lastname: Okada
authors.forename: M
authors.initials: M
authors.lastname: Hosokawa
authors.forename: I
authors.initials: I
authors.lastname: Saiki
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D003043:Cocarcinogenesis; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000627:therapeutic use*; D005354:Fibrosarcoma / Q000473:pathology / Q000517:prevention & control*; D005547:Foreign Bodies; D005780:Gelatin; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D014407:Tumor Cells, Cultured
chemical_list: D004365:Drugs, Chinese Herbal; D005780:Gelatin